A Randomized, Open Label, Controlled, Phase 2, Multi-Center Study to Assess Safety, Tolerability and Efficacy of Adjunctive Treatment With Topically Applied MBN-101 (Pravibismane Topical Suspension) in Subjects With Moderate Diabetic Foot Infection (DFI)
Latest Information Update: 19 Nov 2024
At a glance
- Drugs Pravibismane (Primary) ; Antibacterials
- Indications Diabetic foot ulcer
- Focus Adverse reactions; Proof of concept
- Sponsors Microbion Corporation
Most Recent Events
- 13 Nov 2024 Primary endpoint(Proportion of patients with adverse events) has been met, according to Results presented in the Microbion Corporation media release.
- 13 Nov 2024 Results presented in the Microbion Corporation media release.
- 20 Aug 2024 Status changed from active, no longer recruiting to completed.